Ropsacitinib

N/A

Report date: 2022/09/07 17:03:01
NME

Base Information

Drug NameRopsacitinib
Drug Alias NamePF-06826647
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase 2 inhibitors
TargetsTyrosine-protein kinase 2
Therapy Area/IndicationsPlaque psoriasisPsoriasisColitis, Ulcerative +[4
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[7
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsColitis, UlcerativeHidradenitis Suppurativa
Inactive IndicationsPlaque psoriasisPsoriasis

Other Information

ATC CodeN/A
Related LinksN/A